Fund Holdings — CAXTON CORP

Total Portfolio Value
$4.02M
Total Bought
$570.4K
Total Sold
$727.1K
Net Transaction
-$156.6K
Filing Period:
Securities
▲▼
SharesValue ($K)
Q4 2025
▲▼
Q1 2026
▲▼
Change
▲▼
Q4 2025
▲▼
Q1 2026
▲▼
Weight (%)
▲▼
Change
▲▼
SPDR GOLD TR(GLD)6,9647,623+6592,7603,28081.50%+520
ALX ONCOLOGY HLDGS INC(ALXO)020,946+20,9460421.04%+42
X4 PHARMACEUTICALS INC(XFOR)15,55715,557062641.60%+2
BERKSHIRE HATHAWAY INC DEL710727+173573488.66%-8
INHIBIKASE THERAPEUTICS INC(IKT)28,45328,453058481.19%-11
KYVERNA THERAPEUTICS INC(KYTX)18,77318,77301761624.03%-14
CONTEXT THERAPEUTICS INC(CNTX)18,4030-18,403270—-27
SAB BIOTHERAPEUTICS INC(SABS)10,5270-10,527390—-39
LEXEO THERAPEUTICS INC(LXEO)13,94313,9430138801.99%-58
COMPASS THERAPEUTICS INC(CMPX)29,4950-29,4951580—-158
MIND MEDICINE MINDMED INC15,6880-15,6882100—-210
SPYRE THERAPEUTICS INC(SYRE)8,9190-8,9192920—-292
Page 1 of 1
CAXTON CORP — 13F Holdings — Q1 2026 | TickerTrail